Study directory

Schizophrenia studies

Compare studies and check their requirements with the research team.

Back to overview
More filters: keywords, city, remote
4306studies shown
Showing 937-948 of 4,306
Behavioral study icon
CompletedNCT06067984

Second Course of a Digital Therapeutic for schizophrenia

This study is completed in the United States. It is testing second Course of a Digital Therapeutic for schizophrenia.

In New York
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralOver 18 Years
Countries
United States
Sponsor
Click Therapeutics, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT02970929

An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugA study involving a medication or substance.From 18 Years to 40 Years
Countries
United States, Hungary, Romania, ...
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT05741528

An Extension Study to a Clinical Study That Will Continue Effectiveness and Safety of SEP-363856 in People With Schizophrenia That Switch to SEP-363856 From Their From Their Current Antipsychotic Medication

This study is completed in the United States. It focuses on schizophrenia.

Multiple locations, including Anaheim
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT05304767

Safety study of KarXT in schizophrenia

This study is completed in the United States, in Bulgaria, in Japan, .... It is testing KarXT for schizophrenia.

Multiple locations, including Phoenix
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Bulgaria, Japan, ...
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
CompletedNCT04659174

Safety study of Long-term Safety, Tolerability, and Efficacy of KarXT in schizophrenia

This study is completed in the United States and in Ukraine. It is testing Long-term Safety, Tolerability, and Efficacy of KarXT for schizophrenia.

Multiple locations, including Bentonville
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States, Ukraine
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Other study type icon
UnknownNCT05870722

An In Depth Study Evaluating The Experiences of Patients In Schizophrenia Research

This summary needs review. Please check the official study record and contact the research team for details.

Location not clearly listed
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalA study where researchers collect information without assigning a treatment.Over 18 Years
Countries
Sponsor
Power Life Sciences Inc.
Condition
Schizophrenia
Other study type icon
CompletedNCT00448630

An Observational Study On Metabolic Syndrome Parameters In Schizophrenia Patients Treated With Atypical Antipsychotics

This summary needs review. Please check the official study record and contact the research team for details.

Multiple locations, including Kurttepe
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaObservationalFrom 18 Years to 55 Years
Countries
Türkiye
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT04820309

Safety study of Long-term Safety, Tolerability, and Efficacy of KarXT in schizophrenia

This study is completed in the United States. It is testing Long-term Safety, Tolerability, and Efficacy of KarXT for schizophrenia.

Multiple locations, including Little Rock
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
TerminatedNCT05643170

Effectiveness of Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in schizophrenia

This study was terminated in the United States. It is testing Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT for schizophrenia.

Multiple locations, including Atlanta
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 65 Years
Countries
United States
Sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Condition
Schizophrenia
Drug study icon
CompletedNCT06315283

An study to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in people with Schizophrenia

This study is completed in the United States, in the United Kingdom, in Croatia, .... It focuses on schizophrenia.

Multiple locations, including Los Alamitos
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaDrugFrom 18 Years to 64 Years
Countries
United States, United Kingdom, Croatia, ...
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Condition
Schizophrenia
Behavioral study icon
CompletedNCT01514682

Anti-Inflammatory Treatment of Schizophrenia

This summary needs review. Please check the official study record and contact the research team for details.

In Baltimore
Why is this study shown?

This study is directly about Schizophrenia.

SchizophreniaBehavioralFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.